Adagio Medical Fortifies Leadership for Commercial Push of Novel Heart Arrhythmia Tech

LAGUNA HILLS, Calif. – December 22, 2025 – Adagio Medical Holdings, Inc. (Nasdaq: ADGM) is strategically bolstering its leadership team as it pivots from clinical development to commercialization, announcing the appointment of two seasoned executives to spearhead its market entry. The company has named Marie-Claude Jacques as Senior Vice President of Global Sales and Antwan Gipson as Senior Vice President of Manufacturing and Operations, signaling a major step toward the planned 2026 launch of its proprietary cardiac ablation platform.

The hires come at a critical juncture for the medical device innovator, which is focused on treating complex cardiac arrhythmias. Adagio is preparing to bring its Ultra-Low Temperature Cardiac Ablation (ULTC) technology to a wider market, a move that requires a robust commercial strategy and a scalable manufacturing infrastructure.

“These appointments represent a significant milestone as Adagio prepares for commercialization of our proprietary Ultra-Low Temperature Cardiac Ablation technology for electrophysiology,” said Todd Usen, Chief Executive Officer of Adagio Medical. Usen emphasized the complementary expertise the new leaders bring as the company readies its ULTC ablation platform for a highly anticipated commercial debut.

Building a Global Commercial Powerhouse

Leading the charge on the sales front is Marie-Claude Jacques, an executive with a formidable track record of launching disruptive technologies in the competitive electrophysiology (EP) space. With over 15 years of commercial leadership experience, Ms. Jacques is known for her ability to build high-performing sales organizations and drive physician adoption of novel medical devices.

Her tenure at Baylis Medical is particularly noteworthy. There, she was instrumental in introducing a new energy source into the established EP market, a challenging feat for a smaller company. She built and led a 100-person commercial team, scaling the company’s EP and transseptal access portfolio to over $170 million in annual revenue and achieving consistent double-digit growth. The success culminated in the acquisition of Baylis by medical device giant Boston Scientific, where she subsequently served as a Vice President of sales.

Most recently, as Chief Commercial Officer at Catheter Precision, she led the global commercial launches for VIVO™, a non-invasive 3D mapping system, and LockeT™, a venous closure device. Her experience demonstrates a consistent ability to not only develop markets but also to execute successful product launches from the ground up.

“It is an honor to be a member of this incredible team at Adagio and to be a part of the future of ULTC,” said Ms. Jacques. “I am excited to help build a world-class global commercial organization that will partner with electrophysiologists to redefine outcomes in complex arrhythmia patients with this powerful new tool.”

Engineering a Scalable Manufacturing Engine

Complementing the commercial push, Antwan Gipson will oversee the crucial task of scaling manufacturing and operations. With over two decades of experience, Mr. Gipson brings a wealth of knowledge in building compliant and efficient production infrastructures for energy-based and catheter-based devices within high-growth organizations.

His career is marked by impressive achievements in operational excellence. He has a proven track record of scaling manufacturing from the proof-of-concept stage through to full commercial launch, often increasing production capacity by ten to 100-fold under compressed timelines. Furthermore, his expertise in process optimization has led to reductions in cost of goods by up to 75%—a critical factor for ensuring long-term profitability and commercial sustainability. Mr. Gipson has also been responsible for building audit-ready quality systems that have successfully supported numerous regulatory clearances, a non-negotiable requirement in the medical device industry.

His previous senior leadership roles at Candesant Biomedical, Nano Precision Medical, and Tautona Group have prepared him for the challenge of establishing a global supply chain for Adagio's sophisticated technology.

“Adagio’s technology platform presents a rare opportunity to combine precision engineering with transformative patient impact,” said Mr. Gipson. “I look forward to building a scalable, cost-efficient, and high-quality manufacturing infrastructure that not only supports efficient global supply, but enables attractive gross margins and long-term commercial sustainability.”

The Technology at the Heart of the Push

The strategic hires are centered around Adagio’s novel ULTC technology and its purpose-built vCLAS™ Cryoablation System. Unlike traditional ablation methods, ULTC is designed to create large, durable lesions that can penetrate through the full depth of both diseased and healthy cardiac tissue. This capability is particularly promising for treating ventricular tachycardia (VT), a serious and often life-threatening arrhythmia, especially in patients with structural heart disease.

The vCLAS™ system has already earned a CE Mark, making it commercially available for the treatment of monomorphic VT in Europe and other select regions. In the United States, the system remains under investigational use and is the subject of the FULCRUM-VT pivotal trial.

This prospective, multi-center study has fully enrolled 209 patients with drug-refractory VT, and its results will form the basis of a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA). A successful outcome could grant Adagio the broadest industry indication for a purely endocardial ablation system for scar-mediated VT, potentially positioning it as a first-line therapy for a challenging patient population.

As the company moves forward, the combined expertise of its new leaders will be pivotal. “The addition of Marie-Claude and Antwan underscores our focus on execution, scale, and disciplined commercialization,” added CEO Todd Usen. “Their combined leadership will be central to achieving our commercialization goals in 2026 and beyond and to creating lasting value for our patients, customers and shareholders.”